Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
F. Hoffmann-La Roche Ltd New Phase II data show vast majority of patients experiencing no relapses or disability progression Fenebrutinib suppressed acute and chronic MRI lesions Fenebrutinib’s saf...